NVO Takes DKK 4B Monlunabant Hit, Raises Guidance on Wegovy

Novo Nordisk (NVO) reported Q2 2026 adjusted sales of DKK 78.5 billion on August 4, up 7% at constant exchange rates, and raised its full-year outlook. But the company recorded DKK 6.3 billion in non-cash impairment charges on intangible pipeline assets, including DKK 4.0 billion ($580 million) for monlunabant, its next-generation obesity candidate. Shares closed at $44.28.

The numbers

• Ticker: NVO
• Stock price: $44.28 (close August 4)
• Q2 sales: DKK 78.5 billion (+7% adjusted CER)
• Adjusted operating profit: DKK 33.4 billion (+11% CER)
• Reported operating profit: DKK 27.1 billion (-16% CER, weighed by impairments)
• Impairment charges: DKK 6.3 billion (DKK 4.0B for monlunabant)
• H1 sales: DKK 175.3 billion (+18% CER)

The monlunabant write-down

Monlunabant, a CB1 receptor inverse agonist, was supposed to be Novo’s hedge against the semaglutide patent cliff. Novo acquired the program from Inversago for roughly $1 billion in 2023. The DKK 4 billion impairment, roughly 58% of the acquisition value, signals the Phase 2 data de-risked the program downward.

The Phase 2a results showed dose-dependent weight loss but limited additional benefit at higher doses, and the mechanism’s inherent challenge, CB1 receptors are densely expressed in the brain, raised neuropsychiatric safety questions. Earlier CB1-targeting drugs like rimonabant were pulled from the European market in 2008 due to psychiatric side effects. Monlunabant was designed to be peripherally restricted, but the Phase 2 data suggested some central nervous system penetration remained.

Semaglutide carries the load

The core semaglutide franchise remains the engine. Wegovy and Ozempic generated the bulk of DKK 78.5 billion in sales, and the EMA approved both the Wegovy 7.2 mg higher-dose pen and an oral Wegovy pill during the quarter, supporting continued growth in Europe. Novo raised its full-year adjusted sales and operating profit outlook on the strength of these approvals.

A second pipeline setback came from ziltivekimab, an IL-6 inhibitor that missed its primary endpoint in the ZEUS Phase 3 cardiovascular outcomes trial. The ZEUS failure eliminated one of Novo’s bets on inflammation-driven cardiovascular disease, a strategy competitors are pursuing with drugs like canakinumab and colchicine.

What to watch

Novo’s near-term story is semaglutide maximization: higher-dose Wegovy, the oral pill, and label expansions into MASH, Alzheimer’s, and kidney disease. The longer-term risk is the pipeline beyond GLP-1. With monlunabant impaired and ziltivekimab dead, Novo’s next-generation bets narrowed to CagriSema (amylin/GLP-1 combo) and oral amycretin. The GLP-1 market is projected at $100 billion, but semaglutide’s patent expiration in the early 2030s leaves a narrow window to establish follow-on revenue.

Novo Nordisk Q2 2026 press release